Abeona Therapeutics (ABEO) Competitors

$5.83 -0.12 (-2.02%)

Closing price 04:00 PM Eastern

Extended Trading

$5.90 +0.07 (+1.25%)

As of 06:31 PM Eastern

ABEO vs. CALT, PHAR, URGN, AKTS, and QURE

Should you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Pharming Group (PHAR), Urogen Pharma (URGN), Aktis Oncology (AKTS), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry.

How does Abeona Therapeutics compare to Calliditas Therapeutics AB (publ)?

Abeona Therapeutics (NASDAQ:ABEO) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

: Abeona Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.
: 80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 6.9% of Abeona Therapeutics shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Abeona Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Abeona Therapeutics' return on equity of -60.65% beat Calliditas Therapeutics AB (publ)'s return on equity.
Company Net Margins Return on Equity Return on Assets
Abeona Therapeutics N/A -60.65% -40.78%
Calliditas Therapeutics AB (publ) -30.18% -212.04% -27.96%
: Abeona Therapeutics currently has a consensus price target of $19.00, suggesting a potential upside of 225.90%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Abeona Therapeutics is more favorable than Calliditas Therapeutics AB (publ).
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics
1 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
Calliditas Therapeutics AB (publ)
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Abeona Therapeutics had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for Abeona Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Abeona Therapeutics' average media sentiment score of 0.74 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Abeona Therapeutics Positive
Calliditas Therapeutics AB (publ) Neutral
: Abeona Therapeutics has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abeona Therapeutics $5.82M 56.98 $71.18M $1.03 5.66
Calliditas Therapeutics AB (publ) $1.60B 0.74 -$43.96M -$1.85 N/A

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-60.65%	-40.78%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Abeona Therapeutics	Positive
Calliditas Therapeutics AB (publ)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	56.98	$71.18M	$1.03	5.66
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Summary

Abeona Therapeutics beats Calliditas Therapeutics AB (publ) on 13 of the 16 factors compared between the two stocks.

How does Abeona Therapeutics compare to Pharming Group?

Abeona Therapeutics (NASDAQ:ABEO) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

: Abeona Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500.
: 80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 6.9% of Abeona Therapeutics shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Pharming Group has a net margin of 0.71% compared to Abeona Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 1.08% beat Abeona Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Abeona Therapeutics N/A -60.65% -40.78%
Pharming Group 0.71% 1.08% 0.59%
: Abeona Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 225.90%. Pharming Group has a consensus price target of $38.33, indicating a potential upside of 137.06%. Given Abeona Therapeutics' higher probable upside, research analysts clearly believe Abeona Therapeutics is more favorable than Pharming Group.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics
1 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
Pharming Group
0 Sell rating(s)

2 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.60
: In the previous week, Abeona Therapeutics had 1 more articles in the media than Pharming Group. MarketBeat recorded 4 mentions for Abeona Therapeutics and 3 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.95 beat Abeona Therapeutics' score of 0.74 indicating that Pharming Group is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abeona Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pharming Group
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Abeona Therapeutics has higher earnings, but lower revenue than Pharming Group. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abeona Therapeutics $5.82M 56.98 $71.18M $1.03 5.66
Pharming Group $376.13M 3.04 $2.85M $0.01 1,617.00

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-60.65%	-40.78%
Pharming Group	0.71%	1.08%	0.59%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pharming Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	56.98	$71.18M	$1.03	5.66
Pharming Group	$376.13M	3.04	$2.85M	$0.01	1,617.00

Summary

Abeona Therapeutics beats Pharming Group on 9 of the 15 factors compared between the two stocks.

How does Abeona Therapeutics compare to Urogen Pharma?

Abeona Therapeutics (NASDAQ:ABEO) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

: In the previous week, Abeona Therapeutics had 1 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Abeona Therapeutics and 3 mentions for Urogen Pharma. Abeona Therapeutics' average media sentiment score of 0.74 beat Urogen Pharma's score of 0.42 indicating that Abeona Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abeona Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Urogen Pharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Abeona Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 225.90%. Urogen Pharma has a consensus price target of $34.13, indicating a potential upside of 43.20%. Given Abeona Therapeutics' higher probable upside, research analysts clearly believe Abeona Therapeutics is more favorable than Urogen Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics
1 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
Urogen Pharma
1 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.78
: Abeona Therapeutics has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abeona Therapeutics $5.82M 56.98 $71.18M $1.03 5.66
Urogen Pharma $109.79M 10.57 -$153.49M -$3.20 N/A
: Abeona Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.
: 80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 6.9% of Abeona Therapeutics shares are owned by insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Abeona Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -139.81%. Urogen Pharma's return on equity of 0.00% beat Abeona Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Abeona Therapeutics N/A -60.65% -40.78%
Urogen Pharma -139.81% N/A -72.93%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	56.98	$71.18M	$1.03	5.66
Urogen Pharma	$109.79M	10.57	-$153.49M	-$3.20	N/A

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-60.65%	-40.78%
Urogen Pharma	-139.81%	N/A	-72.93%

Summary

Abeona Therapeutics beats Urogen Pharma on 10 of the 17 factors compared between the two stocks.

How does Abeona Therapeutics compare to Aktis Oncology?

Abeona Therapeutics (NASDAQ:ABEO) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

: In the previous week, Aktis Oncology had 2 more articles in the media than Abeona Therapeutics. MarketBeat recorded 6 mentions for Aktis Oncology and 4 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.74 beat Aktis Oncology's score of 0.17 indicating that Abeona Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abeona Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aktis Oncology
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
: Abeona Therapeutics presently has a consensus price target of $19.00, indicating a potential upside of 225.90%. Aktis Oncology has a consensus price target of $32.00, indicating a potential upside of 64.61%. Given Abeona Therapeutics' higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than Aktis Oncology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics
1 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
Aktis Oncology
0 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
3.00
: Abeona Therapeutics has higher earnings, but lower revenue than Aktis Oncology.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abeona Therapeutics $5.82M 56.98 $71.18M $1.03 5.66
Aktis Oncology $6.50M 159.71 N/A N/A N/A
: 80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 6.9% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Aktis Oncology's return on equity of 0.00% beat Abeona Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Abeona Therapeutics N/A -60.65% -40.78%
Aktis Oncology N/A N/A N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aktis Oncology	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	56.98	$71.18M	$1.03	5.66
Aktis Oncology	$6.50M	159.71	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-60.65%	-40.78%
Aktis Oncology	N/A	N/A	N/A

Summary

Aktis Oncology beats Abeona Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Abeona Therapeutics compare to uniQure?

Abeona Therapeutics (NASDAQ:ABEO) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

: Abeona Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.
: Abeona Therapeutics presently has a consensus price target of $19.00, indicating a potential upside of 225.90%. uniQure has a consensus price target of $44.50, indicating a potential upside of 110.30%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than uniQure.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics
1 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
uniQure
1 Sell rating(s)

6 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.53
: Abeona Therapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abeona Therapeutics $5.82M 56.98 $71.18M $1.03 5.66
uniQure $16.10M 82.90 -$198.97M -$3.45 N/A
: 80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 6.9% of Abeona Therapeutics shares are owned by insiders. Comparatively, 4.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: In the previous week, uniQure had 19 more articles in the media than Abeona Therapeutics. MarketBeat recorded 23 mentions for uniQure and 4 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.74 beat uniQure's score of 0.59 indicating that Abeona Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abeona Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
uniQure
6 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
: Abeona Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,236.00%. Abeona Therapeutics' return on equity of -60.65% beat uniQure's return on equity.
Company Net Margins Return on Equity Return on Assets
Abeona Therapeutics N/A -60.65% -40.78%
uniQure -1,236.00% -174.03% -27.41%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	56.98	$71.18M	$1.03	5.66
uniQure	$16.10M	82.90	-$198.97M	-$3.45	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	6 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-60.65%	-40.78%
uniQure	-1,236.00%	-174.03%	-27.41%

Summary

Abeona Therapeutics beats uniQure on 11 of the 16 factors compared between the two stocks.

Get Abeona Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABEO vs. The Competition

Export

Metric	Abeona Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$331.63M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	5.66	38.85	29.04	28.47
Price / Sales	56.98	155.53	476.61	60.94
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	1.98	7.03	9.67	6.67
Net Income	$71.18M	$23.62M	$3.55B	$332.53M
7 Day Performance	8.77%	3.67%	1.70%	2.01%
1 Month Performance	20.95%	7.16%	5.62%	9.20%
1 Year Performance	-8.91%	67.03%	34.42%	39.59%

Abeona Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABEO Abeona Therapeutics	2.7471 of 5 stars	$5.83 -2.0%	$19.00 +225.9%	N/A	$331.63M	$5.82M	5.66	90	News Coverage Positive News
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
PHAR Pharming Group	4.4493 of 5 stars	$16.92 +1.4%	$38.33 +126.6%	N/A	$1.18B	$376.13M	1,692.00	280	News Coverage Upcoming Earnings
URGN Urogen Pharma	2.9363 of 5 stars	$23.77 -1.4%	$34.13 +43.6%	N/A	$1.17B	$109.79M	N/A	200	Upcoming Earnings
AKTS Aktis Oncology	1.7834 of 5 stars	$20.09 -5.5%	$32.00 +59.3%	N/A	$1.14B	$6.50M	N/A	76	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABEO) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abeona Therapeutics (ABEO) Competitors

ABEO vs. CALT, PHAR, URGN, AKTS, and QURE

How does Abeona Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Abeona Therapeutics compare to Pharming Group?

Summary

How does Abeona Therapeutics compare to Urogen Pharma?

Summary

How does Abeona Therapeutics compare to Aktis Oncology?

Summary

How does Abeona Therapeutics compare to uniQure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abeona Therapeutics (ABEO) Competitors

ABEO vs. CALT, PHAR, URGN, AKTS, and QURE

How does Abeona Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Abeona Therapeutics compare to Pharming Group?

Summary

How does Abeona Therapeutics compare to Urogen Pharma?

Summary

How does Abeona Therapeutics compare to Aktis Oncology?

Summary

How does Abeona Therapeutics compare to uniQure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools